Allgemein- und Viszeralchirurgie up2date, Table of Contents Allgemein- und Viszeralchirurgie up2date 2014; 8(3): 199-214DOI: 10.1055/s-0033-1357932 Oberer Gastrointestinaltrakt Georg Thieme Verlag KG Stuttgart · New York Multimodale Therapie des Ösophaguskarzinoms: Pro und Kontra A. H. Hölscher 1 Klinik und Poliklinik für Allgemein-, Viszeral- und Tumorchirurgie der Universität Köln , U. K. Fetzner 1 Klinik und Poliklinik für Allgemein-, Viszeral- und Tumorchirurgie der Universität Köln , F. G. Uzunoğlu 2 Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Zentrum für Operative Medizin Universitätsklinikum Hamburg-Eppendorf , J. R. Izbicki 2 Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Zentrum für Operative Medizin Universitätsklinikum Hamburg-Eppendorf › Author Affiliations Recommend Article Abstract Buy Article All articles of this category Dieser Beitrag wägt das Für und Wider der multimodalen Therapie des Ösophaguskarzinoms ab und stellt die Behandlungsoptionen der verschiedenen Vorgehensweisen dar. Anhand wissenschaftlicher Daten werden die Argumente pro und kontra multimodale Therapie für Adeno- und Plattenepithelkarzinome des Ösophagus erörtert. Full Text References Quellenangaben (Teil Pro) Arnott SJ, Duncan W, Gignoux M et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; (4) CD001799 Bhansali MS, Vaidya JS, Bhatt RG et al. Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann Oncol 1996; 7: 355-359 Bollschweiler E, Metzger R, Drebber U et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-238 Bollschweiler E, Hölscher AH, Metzger R et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg 2011; 92: 2020-2027 Burmeister BH, Thomas JM et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. EJC 2011; 47: 354-360 Fiorica F, Di Bona D, Schepis F et al. Preoperatlve chemoradiotherapy for esophageal cancer: a systematic revlew and meta-analysis. Gut 2004; 53: 925-930 Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234 Greer S, Goodney P, Sutton J et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005; 137: 172-177 Hölscher AH, Lordick F. Chirurgische und internistische Diagnostik und Therapie des Ösophaguskarzinomes – Update. Gastroenterologie up2date 2012; 8: 103-128 Jin HL, Zhu H, Ling TS et al. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 2009; 15: 5983-5991 Kaklamanos IG, Walker GR, Ferry K et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10: 754-761 Kranzfelder M, Schuster T, Geinitz H et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 2011; 98: 768-783 Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805 Malthaner R, Wong R, Rumble R et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35 Ronellenfitsch U, Schwarzbach M, Hofheinz R et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev 2013; (5) CD008107 Ruol A, Rizzetto C, Castoro C et al. Interval between neoadjuvant chemoradiotherapy and surgery for surgery for squamous cell cancer of the thoracic esophagus. Ann Surg 2010; 252: 788-796 Schneider PM, Baldus SE, Metzger R et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684-692 Sjöquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for respectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692 Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-279 Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543 Vallböhmer D, Hölscher AH, DeMeester S et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg 2010; 252: 744-749 Van Hagen P, Hulshof MCCM et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084 Vogt K, Fenlon D, Rhodes S. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2006; (3) CD001556 Wang DB, Zhang X, Han HL et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci 2012; 57: 3226-3233 Xu Y, Yu X, Chen Q et al. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?. World J Surg Oncol 2012; 10: 173 Zhang CD, Zeng YJ, Li HW. Neoadjuvant chemotherapy for nonmetastatlc esophago-gastric adenocarcinomas: a systematlc review and meta-analysis. Cancer Invest 2013; 31: 421-431 Quellenangaben (Teil Kontra) Crabtree TD, Kosinski AS, Puri V et al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg 2013; 96: 382-390 Dittrick GW, Weber JM, Shridhar R et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol 2012; 19: 1678-1684 Kersting S, Konopke R, Dittert D et al. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. J Gastroenterol Hepatol 2009; 24: 886-895 Kutup A, Link BC, Schurr PG M et al. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy 2007; 39: 715-719 Kutup A, Nentwich MF, Bollschweiler E et al. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic vs. transhiatal esophagectomy. Ann Surg 2013; (in press) NCCN Guidelines, Esophageal and Esophagogastruc Junction Cancers, Version 2.2013, Abschnitt ESOPH-3. Omloo JM, Lagarde SM, Hulscher JB et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000 Reeh M, Mina S, Bockhorn M et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg 2012; 99: 1406-1414 Puli SR, Reddy JB, Bechtold ML et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490 Sasako M, Sano T, Yamamoto S et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644-651 Taylor MD, LaPar DJ, Davis JP et al. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging. Ann Thorac Surg 2013; 96: 225-230: discussion 30 – 31 van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084 Zhang JQ, Hooker CM, Brock MV et al. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann Thorac Surg 2012; 93: 429-435 discussion 36 – 37 Zum Weiterlesen und Vertiefen (Teil Kontra) Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011; 71: 541-555 Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. Cancer Control 2013; 20: 89-96 Fokas E, Weiss C, Rodel C. The role of radiotherapy in the multimodal management of esophageal cancer. Dig Dis 2013; 31: 30-37 Shridhar R, Almhanna K, Meredith KL et al. Radiation therapy and esophageal cancer. Cancer Control 2013; 20: 97-110
